NACTN study gains momentum - Blog - Reeve Foundation

The Christopher & Dana Reeve Foundation's North American Clinical Trials Network (NACTN), with funding from the Department of Defense (DOD), is partnering with AOSpine North America in RISCIS (Riluzole in Spinal Cord Injury Study). The Phase II/III clinical trial is a multi-center, randomized, placebo-controlled double-blinded study that will enroll 351 patients with acute cervical spinal cord injuries. The DOD funding also enables NACTN sites to conduct a RISCIS sub-study, the pharmacology of riluzole, to determine optimal dosage of the drug.

Learn more by visiting our Research page.

   Join Our Movement

What started as an idea has become a national movement. With your support, we can influence policy and inspire lasting change.

Become an Advocate

About the Author - Reeve Staff

This blog was written by the Reeve Foundation for educational purposes. For more information please reach out to

Reeve Staff

The opinions expressed in these blogs are the author's own and do not necessarily reflect the views of the Christopher & Dana Reeve Foundation.